DD202432A5 - Verfahren zur herstellung von naftridrofurylzitrat - Google Patents

Verfahren zur herstellung von naftridrofurylzitrat Download PDF

Info

Publication number
DD202432A5
DD202432A5 DD82239879A DD23987982A DD202432A5 DD 202432 A5 DD202432 A5 DD 202432A5 DD 82239879 A DD82239879 A DD 82239879A DD 23987982 A DD23987982 A DD 23987982A DD 202432 A5 DD202432 A5 DD 202432A5
Authority
DD
German Democratic Republic
Prior art keywords
citrate
naftidrofuryl
oxalate
administration
naftidrofury
Prior art date
Application number
DD82239879A
Other languages
German (de)
English (en)
Inventor
Carlo Blasioli
Jacques A Chick
Alain Heymes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9258433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD202432(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DD202432A5 publication Critical patent/DD202432A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DD82239879A 1981-05-14 1982-05-14 Verfahren zur herstellung von naftridrofurylzitrat DD202432A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8109590A FR2505836A1 (fr) 1981-05-14 1981-05-14 Citrate de naftidrofuryl et son application therapeutique

Publications (1)

Publication Number Publication Date
DD202432A5 true DD202432A5 (de) 1983-09-14

Family

ID=9258433

Family Applications (1)

Application Number Title Priority Date Filing Date
DD82239879A DD202432A5 (de) 1981-05-14 1982-05-14 Verfahren zur herstellung von naftridrofurylzitrat

Country Status (22)

Country Link
US (1) US4439442A (es)
EP (1) EP0065446B1 (es)
JP (1) JPS57203078A (es)
KR (1) KR830010091A (es)
AT (1) ATE9342T1 (es)
AU (1) AU8373282A (es)
CA (1) CA1184562A (es)
CS (1) CS239923B2 (es)
DD (1) DD202432A5 (es)
DE (1) DE3260712D1 (es)
DK (1) DK210982A (es)
ES (1) ES8304559A1 (es)
FI (1) FI821664L (es)
FR (1) FR2505836A1 (es)
GR (1) GR75422B (es)
HU (1) HU187701B (es)
IL (1) IL65774A (es)
NZ (1) NZ200594A (es)
PT (1) PT74893B (es)
SU (1) SU1082323A3 (es)
YU (1) YU103082A (es)
ZA (1) ZA823195B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8203109B2 (en) 2009-05-08 2012-06-19 Raytheon Company High energy laser beam director system and method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2580502B1 (fr) * 1985-04-23 1988-07-08 Lipha Emploi du " naftidrofuryl " dans la preparation d'un medicament
TW200920348A (en) * 2007-06-28 2009-05-16 Dybly Ag Combination of picotamide with nafronyl
CN104086515A (zh) * 2014-06-13 2014-10-08 刘博� 萘呋胺酯草酸盐的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL142872C (es) * 1963-03-28
FR3843M (fr) * 1964-03-17 1966-01-17 Lipha Nouvelles bases azotées a propriétés antispasmodique et vasodilatatrice.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8203109B2 (en) 2009-05-08 2012-06-19 Raytheon Company High energy laser beam director system and method

Also Published As

Publication number Publication date
CS239923B2 (en) 1986-01-16
PT74893A (fr) 1982-06-01
FR2505836B1 (es) 1984-03-09
PT74893B (fr) 1983-12-23
YU103082A (en) 1984-08-31
CA1184562A (fr) 1985-03-26
IL65774A (en) 1985-09-29
EP0065446B1 (fr) 1984-09-12
JPS57203078A (en) 1982-12-13
US4439442B1 (es) 1987-06-30
FR2505836A1 (fr) 1982-11-19
AU8373282A (en) 1982-11-18
FI821664L (fi) 1982-11-15
DK210982A (da) 1982-11-15
FI821664A0 (fi) 1982-05-11
KR830010091A (ko) 1983-12-26
US4439442A (en) 1984-03-27
NZ200594A (en) 1985-03-20
IL65774A0 (en) 1982-08-31
ZA823195B (en) 1983-03-30
HU187701B (en) 1986-02-28
EP0065446A1 (fr) 1982-11-24
SU1082323A3 (ru) 1984-03-23
ES512819A0 (es) 1983-03-01
GR75422B (es) 1984-07-16
ES8304559A1 (es) 1983-03-01
DE3260712D1 (en) 1984-10-18
ATE9342T1 (de) 1984-09-15

Similar Documents

Publication Publication Date Title
DE2904552C2 (de) 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridin-3,5-dicarbonsäure-3-(1-benzylpyrrolidin-3-yl)ester-5-niedrigalkylester
DE2655883C2 (es)
DE2310918B2 (de) 3-lsobutoxy-2-pyrrolidino-N-phenyl-N-benzylpropylamin, dessen Salze, Verfahren zu deren Herstellung und Arzneimittel
DE1670827B2 (de) 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-di carbmethoxy-1,4-dihydropyridin
EP0038438A2 (de) Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel
DE2403122C2 (es)
DE1767163C3 (de) Blutdrucksenkendes Arzneimittel
DD202432A5 (de) Verfahren zur herstellung von naftridrofurylzitrat
DE2951671C2 (de) Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der Blutplättchen
DE2460929C2 (es)
DE2635209C2 (de) 4-(2-Benzoyloxy-3-tert.butylamino-propoxy)-2-methylindol, dessen (S)-Enantiomeres, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Heilmittel
DE3035480A1 (de) Pharmazeutische zusammensetzung zur behandlung von herzstoerungen
DE1470074C3 (de) 1,2,3,4,6,7-Hexahydro-l lbH-benzo eckige Klammer auf a eckige Klammer zu chinolizine sowie deren Acetate und/oder phsiologisch verträgliche Säureadditionssalze sowie Verfahren zu ihrer Herstellung
DE69032046T2 (de) Tetrahydroisochinolinylcarbamate von 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo [2,3-b] indol
EP0524512B1 (de) Antihypertensive Kombination
DE68912740T2 (de) Azazyklische Derivate mit harntreibender Wirkung.
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum
EP0032564A1 (de) Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest
DE2835043A1 (de) Bromhexin-derivate mit gegenueber bromhexin geringerer schleimloesender und hustenlindernder wirkung und geringerer toxizitaet
DE1792764A1 (de) Kreislaufbeeinflussende mittel
DE2749075C2 (es)
DE1470012B2 (de) Papaverinsalz der 7-theophyllin-n- propan-omega-sulfonsaeure
DE4430094A1 (de) Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel
EP0005732A1 (de) Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris
EP0334164B1 (de) Antihypertensives Kombinationspräparat